Literature DB >> 32676851

Four-Repeat Tauopathies: Current Management and Future Treatments.

Lawren VandeVrede1, Peter A Ljubenkov2, Julio C Rojas2, Ariane E Welch2, Adam L Boxer2.   

Abstract

Four-repeat tauopathies are a neurodegenerative disease characterized by brain parenchymal accumulation of a specific isoform of the protein tau, which gives rise to a wide breadth of clinical syndromes encompassing diverse symptomatology, with the most common syndromes being progressive supranuclear palsy-Richardson's and corticobasal syndrome. Despite the lack of effective disease-modifying therapies, targeted treatment of symptoms can improve quality of life for patients with 4-repeat tauopathies. However, managing these symptoms can be a daunting task, even for those familiar with the diseases, as they span motor, sensory, cognitive, affective, autonomic, and behavioral domains. This review describes current approaches to symptomatic management of common clinical symptoms in 4-repeat tauopathies with a focus on practical patient management, including pharmacologic and nonpharmacologic strategies, and concludes with a discussion of the history and future of disease-modifying therapeutics and clinical trials in this population.

Entities:  

Keywords:  4R-tauopathy (4R-tau); Richardson’s syndrome (PSP-RS); atypical parkinsonism; corticobasal degeneration (CBD); corticobasal syndrome (CBS); progressive supranuclear palsy (PSP)

Mesh:

Year:  2020        PMID: 32676851      PMCID: PMC7851277          DOI: 10.1007/s13311-020-00888-5

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  176 in total

Review 1.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  Office of Rare Diseases neuropathologic criteria for corticobasal degeneration.

Authors:  D W Dickson; C Bergeron; S S Chin; C Duyckaerts; D Horoupian; K Ikeda; K Jellinger; P L Lantos; C F Lippa; S S Mirra; M Tabaton; J P Vonsattel; K Wakabayashi; I Litvan
Journal:  J Neuropathol Exp Neurol       Date:  2002-11       Impact factor: 3.685

Review 3.  Neuropathology of variants of progressive supranuclear palsy.

Authors:  Dennis W Dickson; Zeshan Ahmed; Avi A Algom; Yoshio Tsuboi; Keith A Josephs
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

Review 4.  Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies.

Authors:  M G Spillantini; T D Bird; B Ghetti
Journal:  Brain Pathol       Date:  1998-04       Impact factor: 6.508

Review 5.  Invited review: Neuropathology of tauopathies: principles and practice.

Authors:  G G Kovacs
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

6.  Criteria for the diagnosis of corticobasal degeneration.

Authors:  Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner
Journal:  Neurology       Date:  2013-01-29       Impact factor: 9.910

7.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

8.  Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization.

Authors:  M Goedert; R Jakes
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

9.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

10.  Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes.

Authors:  Ian T S Coyle-Gilchrist; Katrina M Dick; Karalyn Patterson; Patricia Vázquez Rodríquez; Eileen Wehmann; Alicia Wilcox; Claire J Lansdall; Kate E Dawson; Julie Wiggins; Simon Mead; Carol Brayne; James B Rowe
Journal:  Neurology       Date:  2016-04-01       Impact factor: 9.910

View more
  7 in total

1.  Therapeutic Advances in Movement Disorders.

Authors:  Caroline M Tanner; Jill L Ostrem
Journal:  Neurotherapeutics       Date:  2021-01-15       Impact factor: 7.620

Review 2.  Therapeutic strategies for tauopathies and drug repurposing as a potential approach.

Authors:  Majedul Islam; Fengyun Shen; Deepika Regmi; Deguo Du
Journal:  Biochem Pharmacol       Date:  2022-02-24       Impact factor: 6.100

Review 3.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

4.  Uniform data set language measures for bvFTD and PPA diagnosis and monitoring.

Authors:  Adam M Staffaroni; Sandra Weintraub; Katya Rascovsky; Katherine P Rankin; Jack Taylor; Julie A Fields; Kaitlin B Casaletto; Argye E Hillis; Sladjana Lukic; Maria Luisa Gorno-Tempini; Hilary Heuer; Merilee A Teylan; Walter A Kukull; Bruce L Miller; Bradley F Boeve; Howard J Rosen; Adam L Boxer; Joel H Kramer
Journal:  Alzheimers Dement (Amst)       Date:  2021-02-20

5.  The Disease Associated Tau35 Fragment has an Increased Propensity to Aggregate Compared to Full-Length Tau.

Authors:  Chen Lyu; Stefano Da Vela; Youssra Al-Hilaly; Karen E Marshall; Richard Thorogate; Dmitri Svergun; Louise C Serpell; Annalisa Pastore; Diane P Hanger
Journal:  Front Mol Biosci       Date:  2021-10-28

6.  Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants.

Authors:  Duncan Street; Maura Malpetti; Timothy Rittman; Boyd C P Ghosh; Alexander G Murley; Ian Coyle-Gilchrist; Luca Passamonti; James B Rowe
Journal:  Brain Commun       Date:  2021-09-02

7.  Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  Ignacio Illán-Gala; Salvatore Nigro; Lawren VandeVrede; Neus Falgàs; Hilary W Heuer; Cèlia Painous; Yaroslau Compta; Maria J Martí; Victor Montal; Javier Pagonabarraga; Jaime Kulisevsky; Alberto Lleó; Juan Fortea; Giancarlo Logroscino; Andrea Quattrone; Aldo Quattrone; David C Perry; Maria Luisa Gorno-Tempini; Howard J Rosen; Lea T Grinberg; Salvatore Spina; Renaud La Joie; Gil D Rabinovici; Bruce L Miller; Julio C Rojas; William W Seeley; Adam L Boxer
Journal:  JAMA Netw Open       Date:  2022-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.